These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 11009057)

  • 21. A prospective view on European pharmaceutical research and development. Policy options to reduce fragmentation and increase competitiveness.
    Kanavos P
    Pharmacoeconomics; 1998 Feb; 13(2):181-90. PubMed ID: 10178646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmaceutical Price Schemes in Europe: Time for a 'Continental' One?
    Garattini L; Curto A; Freemantle N
    Pharmacoeconomics; 2016 May; 34(5):423-6. PubMed ID: 26820147
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmaceutical price differences in the EU: investigation from cardiovascular disease drugs.
    Timur A; Picone G
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):251-6. PubMed ID: 19527097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The world population does not have the drugs it needs. WHO report recommends more stringent control of the drug industry].
    Asplund K
    Lakartidningen; 2005 Feb 14-20; 102(7):450-1. PubMed ID: 15768693
    [No Abstract]   [Full Text] [Related]  

  • 25. EU agrees deal on cheaper drugs for developing world.
    Watson R
    BMJ; 2003 Jun; 326(7401):1229. PubMed ID: 12791716
    [No Abstract]   [Full Text] [Related]  

  • 26. EU offers incentives to firms to produce medicines for children.
    Watson R
    BMJ; 2006 Jun; 332(7554):1352. PubMed ID: 16763236
    [No Abstract]   [Full Text] [Related]  

  • 27. Drug shortage crisis resolution.
    Duffy E
    J Pharm Pract; 2012 Dec; 25(6):619-20. PubMed ID: 23222856
    [No Abstract]   [Full Text] [Related]  

  • 28. Regulatory watch: Where do new medicines originate from in the EU?
    Lincker H; Ziogas C; Carr M; Porta N; Eichler HG
    Nat Rev Drug Discov; 2014 Feb; 13(2):92-3. PubMed ID: 24481298
    [No Abstract]   [Full Text] [Related]  

  • 29. VTE: From partnership to prevention.
    Savage S
    Health Serv J; 2012 Apr; 122(6301):26-7. PubMed ID: 22666994
    [No Abstract]   [Full Text] [Related]  

  • 30. Stimulating pharmaceutical innovation in the EU.
    Annemans L; Cleemput I; Hulstaert F; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2011 Jun; 11(3):235-9. PubMed ID: 21671690
    [No Abstract]   [Full Text] [Related]  

  • 31. Drug evaluation and approval process in the European Union.
    San Miguel MT; Vargas E
    Arthritis Rheum; 2006 Feb; 55(1):12-4. PubMed ID: 16463405
    [No Abstract]   [Full Text] [Related]  

  • 32. [The European Union and drugs].
    Viala G; Campion MD
    Ann Pharm Fr; 1995; 53(4):184-7. PubMed ID: 7574273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Developing the latest framework to measure and incentivise pharmaceutical industry contributions to health research and development.
    Cole CB; Trolle S; Edwards DJ
    Health Res Policy Syst; 2018 Aug; 16(1):73. PubMed ID: 30071858
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Eurofile. Private-public drive to cut delays in drug development.
    Mundell I
    Eur J Cancer; 2008 Jan; 44(2):169. PubMed ID: 18335586
    [No Abstract]   [Full Text] [Related]  

  • 35. Proceedings of a symposium: economics and cost-effectiveness in evaluating the value of cardiovascular therapies. What constitutes a useful health economic study for the pharmaceutical industry?
    Gagnon JP
    Am Heart J; 1999 May; 137(5):S62-6. PubMed ID: 10220599
    [No Abstract]   [Full Text] [Related]  

  • 36. Priority medicines and the world.
    Dukes MN
    Bull World Health Organ; 2005 May; 83(5):324. PubMed ID: 15976869
    [No Abstract]   [Full Text] [Related]  

  • 37. White spots in pharmaceutical pipelines-EMA identifies potential areas of unmet medical needs.
    Papaluca M; Greco M; Tognana E; Ehmann F; Saint-Raymond A
    Expert Rev Clin Pharmacol; 2015 May; 8(3):353-60. PubMed ID: 25797498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Future European health care: cost containment, health care reform and scientific progress in drug research.
    Emilien G
    Int J Health Plann Manage; 1997; 12(2):81-101. PubMed ID: 10173136
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Payers growing influence on R&D decision making.
    Hughes B
    Nat Rev Drug Discov; 2008 Nov; 7(11):876-8. PubMed ID: 18974741
    [No Abstract]   [Full Text] [Related]  

  • 40. Inspections: the international regulatory view.
    Turner JL
    PDA J Pharm Sci Technol; 1994; 48(4):180-1. PubMed ID: 7804815
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.